Sanofi UroXatral Approval For BPH Includes Phase IV QT Study Commitment
Executive Summary
Sanofi-Synthelabo's UroXatral Phase IV study will examine potential QT prolongation of alfuzosin in combination with a phosphodiesterase inhibitor erectile dysfunction agent following June 12 approval of the drug
You may also be interested in...
Ranexa Advisory Cmte. Review Cancelled; User Fee Date May Be Extended
CV Therapeutics sees a Ranexa action letter or a user fee date extension as FDA's next possible steps following the cancellation of the angina agent's September review by FDA's Cardiovascular & Renal Drugs Advisory Committee
Ranexa Advisory Cmte. Review Cancelled; User Fee Date May Be Extended
CV Therapeutics sees a Ranexa action letter or a user fee date extension as FDA's next possible steps following the cancellation of the angina agent's September review by FDA's Cardiovascular & Renal Drugs Advisory Committee
CV Therapeutics Ranexa Pre-Launch Steps Will Ramp Up After Cmte. Review
CV Therapeutics expects to begin hiring Ranexa sales reps following the chronic angina therapy's review by FDA's Cardiovascular & Renal Drugs Advisory Committee in September, the company said July 17